Issues related to coverage of medical devices
Breakthrough technology designation associated with medicare reimbursement
Issues related to diagnosis and treatment of structural heart disease
Issues related to medical device tax repeal
Duration: February 14, 2006
to
June 30, 2019
General Issues: Medicare/Medicaid , Health Issues , Taxation/Internal Revenue Code , Medical/Disease Research/Clinical Labs , Torts , Copyright/Patent/Trademark , Trade (Domestic & Foreign) , Budget/Appropriations
Spending: about $2,150,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2006: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS), Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
James Hawkins III Health Policy Advisor, Senate HELP Committee
Courtney Johnson Research Assistant, House Energy and Commerce Cmte
Research Assistant, House Energy & Commerce Committee
J. Michael Hogan Deputy Chief of Staff, Sen. Ben Nelson
JAY HAWKINS Health Policy Advisor, Senate HELP Committee
Rhod Shaw Chief of Staff, Rep. Sherrod Brown (D-OH)
Chief of Staff/LD, Rep. Sherrod Brown (R-OH)
Bob Brooks Chief of Staff, Rep. Jim McCrery (R-LA)
Rebecca Hawes Legislative Counsel, Sen. John Breaux (D-LA)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2019
ALPINE GROUP, INC. terminated an engagement in which they represented Edwards Lifesciences on July 19, 2019.
Original Filing: 301052129.xml
Lobbying Issues
Issues related to coverage of medical devices
Breakthrough technology designation associated with medicare reimbursement
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to diagnosis and treatment of structural heart disease
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to medical device tax repeal
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on April 18, 2019.
Original Filing: 301028957.xml
Lobbying Issues
Issues related to coverage of medical devices
Breakthrough technology designation associated with medicare reimbursement
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to diagnosis and treatment of structural heart disease
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to medical device tax repeal
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Jan. 22, 2019.
Original Filing: 301014079.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
CMS Payment Policies For Medical Devices
HR 5997, Ensuring Patient Access to Critical Breakthrough Pathway Products of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies promoting medical innovation
HR 5997, Ensuring Patient Access to Critical Breakthrough Pathway Products of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 184, Protect Medical Innovation Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Oct. 22, 2018.
Original Filing: 300995102.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
CMS Payment Policies For Medical Devices
HR 5997, Ensuring Patient Access to Critical Breakthrough Pathway Products of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies promoting medical innovation
HR 5997, Ensuring Patient Access to Critical Breakthrough Pathway Products of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 184, Protect Medical Innovation Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on July 19, 2018.
Original Filing: 300970137.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
CMS Payment Policies For Medical Devices
HR 5997, Ensuring Patient Access to Critical Breakthrough Pathway Products of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies promoting medical innovation
HR 5997, Ensuring Patient Access to Critical Breakthrough Pathway Products of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 184, Protect Medical Innovation Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on April 20, 2018.
Original Filing: 300952847.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
CMS Payment Policies For Medical Devices
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies promoting medical innovation
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 184, Protect Medical Innovation Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Jan. 9, 2018.
Original Filing: 300921989.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
CMS Payment Policies For Medical Devices
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies promoting medical innovation
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 184, Protect Medical Innovation Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Oct. 23, 2017.
Original Filing: 300917269.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
CMS Payment Policies For Medical Devices
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies promoting medical innovation
Medical Device User Fees
Postmarket Surveillance
H.R. 1628, American Health Care Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 184, Protect Medical Innovation Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on July 12, 2017.
Original Filing: 300883772.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
CMS Payment Policies For Medical Devices
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies promoting medical innovation
Medical Device User Fees
Postmarket Surveillance
FDA Quality Problems
H.R. 1628, American Health Care Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 184, Protect Medical Innovation Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on May 26, 2017.
Original Filing: 300880611.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
CMS Payment Policies For Medical Devices
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies promoting medical innovation
Medical Device User Fees
Postmarket Surveillance
FDA Quality Problems
H.R. 1628, American Health Care Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 184, Protect Medical Innovation Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Jan. 21, 2017.
Original Filing: 300854051.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
H.R. 6 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
CMS Payment Policies For Medical Devices
Coverage and reimbursement policy for medical devices/THV
H.R. 5009 / S. 2998, Ensuring Patient Access to Critical Breakthrough Products Act of 2016
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6, 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
Policies promoting medical innovation
Medical Device User Fees
Postmarket Surveillance
FDA Quality Problems
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300839224.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
H.R. 6 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
CMS Payment Policies For Medical Devices
Coverage and reimbursement policy for medical devices/THV
H.R. 5009 / S. 2998, Ensuring Patient Access to Critical Breakthrough Products Act of 2016
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6, 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
Policies promoting medical innovation
Medical Device User Fees
Postmarket Surveillance
FDA Quality Problems
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300814779.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
H.R. 6 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
CMS Payment Policies For Medical Devices
Coverage and reimbursement policy for medical devices/THV
H.R. 5009 / S. 2998, Ensuring Patient Access to Critical Breakthrough Products Act of 2016
Agencies Lobbied
U.S. Senate
Lobbying Issues
Taxation of Offshore Income
Tax Reform
Federal Corporate Tax Rate
Repatriation
Domestic Manufacturing Credit
H.R. 160, Protect Medical Innovation Act
S. 149, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
Policies promoting medical innovation
Medical Device User Fees
Postmarket Surveillance
FDA Quality Problems
H.R. 160, Protect Medical Innovation Act
S. 149, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on April 19, 2016.
Original Filing: 300795170.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
H.R. 6 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
CMS Payment Policies For Medical Devices
Agencies Lobbied
U.S. Senate
Lobbying Issues
Innovation Promotion Act of 2015 (Boustany Innovation/Patent Box Leg)
H.R. 1, Tax Reform Act of 2014
Foreign Source Income Tax Deferral
Taxation of Offshore Income
Tax Reform
Federal Corporate Tax Rate
Repatriation
Senate Finance Committee Tax Reform Process
Transfer Pricing
Domestic Manufacturing Credit
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
Policies promoting medical innovation
Medical Device User Fees
Postmarket Surveillance
FDA Quality Problems
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Jan. 20, 2016.
Original Filing: 300781354.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
H.R. 6 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
CMS Payment Policies For Medical Devices
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 160, Protect Medical Innovation Act of 2015
S. 149, Medical Device Access and Innovation Protection Act
Innovation Promotion Act of 2015 (Boustany Innovation/Patent Box Leg)
H.R. 1, Tax Reform Act of 2014
Obama Administration 2016 Budget Proposals
Foreign Source Income Tax Deferral
Taxation of Offshore Income
Tax Reform
Federal Corporate Tax Rate
Repatriation
Transfer Pricing
R&D Tax Credit
Domestic Manufacturing Credit
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
H.R. 160, Protect Medical Innovation Act of 2015
S. 149, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300761108.xml
Lobbying Issues
CMS Coverage Policies for Medical Devices
H.R. 6 21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
CMS Payment Policies For Medical Devices
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 160, Protect Medical Innovation Act of 2015
S. 149, Medical Device Access and Innovation Protection Act
Innovation Promotion Act of 2015 (Boustany Innovation/Patent Box Leg)
H.R. 1, Tax Reform Act of 2014
Obama Administration 2016 Budget Proposals
Senate Finance Committee Tax Reform Process
Foreign Source Income Tax Deferral
Taxation of Offshore Income
Tax Reform
Federal Corporate Tax Rate
Repatriation
Transfer Pricing
R&D Tax Credit
Domestic Manufacturing Credit
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
21st Century Cures Initiative
Senate "Innovation for Healthier Americans" Initiative
H.R. 160, Protect Medical Innovation Act of 2015
S. 149, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on July 20, 2015.
Original Filing: 300743693.xml
Lobbying Issues
CMS Coverage Policies for medical devices
H.R. 6 21st Century Cures Initiative
Senate Innovation Initiative
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 160, Protect Medical Innovation Act of 2015
S. 149, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Implementation of PL-112-144, "Food and Drug Administration Safety and Innovation Act
21st Century Cures Initiative
Senate Innovation Initiative
CMS Coverage and Payment Policies
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on April 20, 2015.
Original Filing: 300722855.xml
Lobbying Issues
CMS Coverage Policies for medical devices
21st Century Cures Initiative
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 160, Protect Medical Innovation Act of 2015
S. 149, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Implementation of PL-112-144, "Food and Drug Administration Safety and Innovation Act
21st Century Cures Initiative
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Jan. 9, 2015.
Original Filing: 300701340.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523, Protect Medical Innovation Act of 2013
S. 232, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Implementation of PL-111-148
Implementation of PL-112-144, "Food and Drug Administration Safety and Innovation Act
Medical Device Post Market Surveillance
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Oct. 3, 2014.
Original Filing: 300678378.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523, Protect Medical Innovation Act of 2013
S. 232, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Implementation of PL-111-148
Implementation of PL-112-144, "Food and Drug Administration Safety and Innovation Act
Medical Device Post Market Surveillance
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on July 17, 2014.
Original Filing: 300660108.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523, Protect Medical Innovation Act of 2013
S. 232, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Implementation of PL-111-148
Implementation of PL-112-144, "Food and Drug Administration Safety and Innovation Act
Medical Device Post Market Surveillance
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on April 16, 2014.
Original Filing: 300637451.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523, Protect Medical Innovation Act of 2013
S. 232, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Implementation of PL-111-148
Implementation of PL-112-144, "Food and Drug Administration Safety and Innovation Act
Medical Device Post Market Surveillance
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616589.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523, Protect Medical Innovation Act of 2013
S. 232, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Implementation of PL-111-148
Issues related to improving outcome in sepsis treatment
Implementation of PL-112-144, "Food and Drug Administration Safety and Innovation Act
Medical Device Post Market Surveillance
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on Oct. 17, 2013.
Original Filing: 300603018.xml
Lobbying Issues
Issues related to improving outcome in sepsis treatment
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523, Protect Medical Innovation Act of 2013
S. 232, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on July 12, 2013.
Original Filing: 300579768.xml
Lobbying Issues
Issues related to improving outcome in sepsis treatment
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523, Protect Medical Innovation Act of 2013
S. 232, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on April 18, 2013.
Original Filing: 300552860.xml
Lobbying Issues
Issues related to improving outcome in sepsis treatment
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 523, Protect Medical Innovation Act of 2013
S. 232, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Jan. 14, 2013.
Original Filing: 300528462.xml
Lobbying Issues
Issues related to improving outcome in sepsis treatment
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 436, Health Care Cost Reduction Act of 2012
S. 17, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2012
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Oct. 19, 2012.
Original Filing: 300512093.xml
Lobbying Issues
Issues related to improving outcome in sepsis treatment
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 436, Health Care Cost Reduction Act of 2012
S. 17, Medical Device Access and Innovation Protection Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2012
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on July 18, 2012.
Original Filing: 300488900.xml
Lobbying Issues
Issues related to improving outcome in sepsis treatment
H.R. 5651, Food and Drug Administration Reform Act of 2012
S. 3187, Food and Drug Administration Safety and Innovation Act
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on April 19, 2012.
Original Filing: 300467409.xml
Lobbying Issues
Implementation of PL-111-148
Medical device user fee implementation
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Jan. 12, 2012.
Original Filing: 300443131.xml
Lobbying Issues
Implementation of PL-111-148
Medical device user fee implementation
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on Oct. 19, 2011.
Original Filing: 300421128.xml
Lobbying Issues
Implementation of PL-111-148
Medical device user fee implementation
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on July 18, 2011.
Original Filing: 300393522.xml
Lobbying Issues
Implementation of PL-111-148
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $50,000. The report was filed on April 19, 2011.
Original Filing: 300369385.xml
Lobbying Issues
Implementation of PL-111-148
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on Jan. 11, 2011.
Original Filing: 300345133.xml
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 506/HR 1265, Stop Tax Haven Abuse Act
tax deferral issues
taxation of offshore income
excise tax of medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2010
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on Oct. 7, 2010.
Original Filing: 300317770.xml
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 506/HR 1265, Stop Tax Haven Abuse Act
tax deferral issues
taxation of offshore income
excise tax of medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2010
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on July 20, 2010.
Original Filing: 300299976.xml
Lobbying Issues
Implementation of PL-111-148
medical device tax
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 540/HR 1346, Medical Device Safety Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 506/HR 1265, Stop Tax Haven Abuse Act
tax deferral issues
taxation of offshore income
excise tax of medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Implementation of PL-111-148
medical device tax
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on April 16, 2010.
Original Filing: 300262872.xml
Lobbying Issues
physician disclosure and comparative effectiveness research
HR 3200, America's Affordable Health Choices Act of 2009
S. 1679, Affordable Health Choices Act
America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 540/HR 1346, Medical Device Safety Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 506/HR 1265, Stop Tax Haven Abuse Act
tax deferral issues
taxation of offshore income
excise tax of medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2009
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on Feb. 20, 2014.
Original Filing: 300630600.xml
Lobbying Issues
physician disclosure and comparative effectiveness research
HR 3200, America's Affordable Health Choices Act of 2009
S. 1679, Affordable Health Choices Act
America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 540/HR 1346, Medical Device Safety Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 506/HR 1265, Stop Tax Haven Abuse Act
tax deferral issues
taxation of offshore income
excise tax of medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2009
In Q4, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on Jan. 11, 2010.
Original Filing: 300233307.xml
Lobbying Issues
physician disclosure and comparative effectiveness research
HR 3200, America's Affordable Health Choices Act of 2009
S. 1679, Affordable Health Choices Act
America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 540/HR 1346, Medical Device Safety Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 506/HR 1265, Stop Tax Haven Abuse Act
tax deferral issues
taxation of offshore income
excise tax of medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2009
In Q3, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on Oct. 8, 2009.
Original Filing: 300214877.xml
Lobbying Issues
physician disclosure and comparative effectiveness research
HR 3200, America's Affordable Health Choices Act of 2009
S. 1679, Affordable Health Choices Act
America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 540/HR 1346, Medical Device Safety Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 506/HR 1265, Stop Tax Haven Abuse Act
tax deferral issues
taxation of offshore income
excise tax of medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2009
In Q2, ALPINE GROUP, INC. lobbied for Edwards Lifesciences , earning $40,000. The report was filed on July 16, 2009.
Original Filing: 300183135.xml
Lobbying Issues
physician disclosure
comparative effectiveness research
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 540/HR 1346, Medical Device Safety Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 506/HR 1265, Stop Tax Haven Abuse Act
tax deferral issues
taxation of offshore income
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 515, Patent Reform Act of 2009
HR 1260, Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2009
In Q1, ALPINE GROUP, INC. lobbied for EDWARDS LIFE SCIENCES , earning $40,000. The report was filed on April 16, 2009.
Original Filing: 300151014.xml
Lobbying Issues
physician disclosure
comparative effectiveness research
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 540/HR 1346, Medical Device Safety Act of 2009
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, ALPINE GROUP, INC. lobbied for EDWARDS LIFE SCIENCES , earning $40,000. The report was filed on Jan. 15, 2009.
Original Filing: 300122101.xml
Lobbying Issues
HR 1321, Medicare Advanced Laboratory Diagnostics Act of 2007
S. 631, Remote Monitoring Access Act of 2007
S. 2221, Transparency in Medical Device Pricing Act of 2007
H.R. 6381, Medical Device Safety Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 appropriations for the FDA
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, ALPINE GROUP, INC. lobbied for EDWARDS LIFE SCIENCES , earning $40,000. The report was filed on Oct. 10, 2008.
Original Filing: 300101528.xml
Lobbying Issues
HR 1321, Medicare Advanced Laboratory Diagnostics Act of 2007
S. 631, Remote Monitoring Access Act of 2007
S. 2221, Transparency in Medical Device Pricing Act of 2007
H.R. 6381, Medical Device Safety Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 appropriations for the FDA
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, ALPINE GROUP, INC. lobbied for EDWARDS LIFE SCIENCES , earning $40,000. The report was filed on July 10, 2008.
Original Filing: 300066052.xml
Lobbying Issues
HR 1321, Medicare Advanced Laboratory Diagnostics Act of 2007
S. 631, Remote Monitoring Access Act of 2007
S. 2221, Transparency in Medical Device Pricing Act of 2007
H.R. 6381, Medical Device Safety Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 appropriations for the FDA
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, ALPINE GROUP, INC. lobbied for EDWARDS LIFE SCIENCES , earning $40,000. The report was filed on April 21, 2008.
Original Filing: 300048153.xml
Lobbying Issues
HR 1321, Medicare Advanced Laboratory Diagnostics Act of 2007
S. 631, Remote Monitoring Access Act of 2007
S. 2221, Transparency in Medical Device Pricing Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2008 appropriations for the FDA
Agencies Lobbied
U.S. House of Representatives
0th Quarter, 2007
In MM, ALPINE GROUP, INC. lobbied for EDWARDS LIFE SCIENCES , earning $80,000. The report was filed on Aug. 6, 2007.
Original Filing: 200046746.xml
Lobbying Issues
HR 1321, Medicare Advanced Laboratory Diagnostics Act of 2007
S. 631, Remote Monitoring Access Act of 2007
Lobbying Issues
FY 2008 appropriations for the FDA
Lobbying Issues
HR 2900, Food and Drug Administration Amendments Act of 2007
S 1082, Prescription Drug User Fee Amendments of 2007
Lobbying Issues
non-tariff trade barriers for medical devices
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2006
Alpine Group, Inc filed a lobbying registration on April 26, 2009 to represent Edwards Lifesciences, effective Feb. 14, 2006.
Original Filing: 300167418.xml
Issue(s) they said they’d lobby about: FDA review of medical devices
Medicare in-patient hospital payments .
1st Quarter, 2006
ALPINE GROUP, INC. filed a lobbying registration on March 15, 2006 to represent Edwards Life Sciences, effective Feb. 14, 2006.
Original Filing: 100022949.xml
Issue(s) they said they’d lobby about: FDA review of medical devices
Medicare inpatient hospital payments .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...